SCHEMBL130593

SCHEMBL130593

Cc1nccc2[nH]cnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.44
DRD1 P21728 3/20 0.43
EGLN1 Q9GZT9 1/20 0.41
BRD4 O60885 1/20 0.40
PDE3B Q13370 2/20 0.40
PDE3A Q14432 2/20 0.40
LMNA P02545 2/20 0.38
PARP1 P09874 1/20 0.38
ALDH1A1 P00352 3/20 0.38
PKM P14618 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
POLB P06746 1/20 0.37
PDPK1 O15530 1/20 0.36
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
PRNP P04156 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4563575 0.78 MMP12 (0.44) MMP12DRD1EGLN1BRD4LMNA
SCHEMBL14889040 0.75 EGLN1 (0.40) MMP12DRD1EGLN1BRD4PDE3B
SCHEMBL19935671 0.74 MMP12 (0.44) MMP12DRD1EGLN1BRD4LMNA
SCHEMBL18301417 0.74 MMP12 (0.51) MMP12DRD1EGLN1PDE3BPDE3A
SCHEMBL2059241 0.74 EGLN1 (0.45) MMP12DRD1EGLN1LMNAPARP1
SCHEMBL563514 0.74 MMP12 (0.44) MMP12DRD1EGLN1LMNAPARP1
SCHEMBL12304499 0.74 LMNA (0.46) MMP12DRD1EGLN1BRD4LMNA
SCHEMBL29424896 0.74 EGLN1 (0.45) MMP12DRD1EGLN1LMNAPARP1
SCHEMBL17248118 0.74 MMP12 (0.41) MMP12DRD1EGLN1BRD4LMNA
SCHEMBL986616 0.74 DRD1 (0.47) MMP12DRD1EGLN1BRD4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912703-B2 6-azaindole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-27 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20230295122-A1 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2023-09-21 US disclosed
US-11427580-B2 6-azaindole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2022-08-30 US disclosed
US-20210403468-A1 SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-12-30 US disclosed
US-20210253593-A1 SUBSTITUTED INDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-08-19 US disclosed
WO-2021115286-A1 SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR 成都倍特药业股份有限公司 2021-06-17 WO disclosed
US-20200385382-A1 6-AZAINDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-12-10 US disclosed
US-20200308172-A1 SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-10-01 US disclosed
US-20170362178-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES KREOS CAPITAL VII (UK) LIMITED (GB) 2017-12-21 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
US-20090270431-A1 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) 2009-10-29 US disclosed
US-5302601-A Useful in the treatment of diseases mediated by platelet activating factor G. D. SEARLE & CO. (US) 1994-04-12 US disclosed
EP-0404797-A4 1H/3H- 4-(N,N-DICYCLOALKYL/BRANCHED-ALKYLCARBOXAMIDO)-BENZYL)IMIDAZO 4,5-C)PYRIDINES AS PAF ANTAGONISTS 1992-01-22 EP disclosed
EP-0404797-A1 1H/3H- 4-(N,N-DICYCLOALKYL/BRANCHED-ALKYLCARBOXAMIDO)-BENZYL]IMIDAZO 4,5-c]PYRIDINES AS PAF ANTAGONISTS. SEARLE & CO (US) 1991-01-02 EP disclosed
WO-1989008653-A1 1H/3H-[4-(N,N-DICYCLOALKYL/BRANCHED-ALKYLCARBOXAMIDO)-BENZYL]IMIDAZO[4,5-c]PYRIDINES AS PAF ANTAGONISTS G.D. SEARLE & CO. (US) 1989-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362178-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES HPD, APEH, P4HA1 MMP12 1706/4885DRD1 1991/4885EGLN1 140/4885
US-20230295122-A1 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS TLR9, TLR1, TLR7 MMP12 939/4885DRD1 2179/4885EGLN1 1875/4885
US-11912703-B2 6-azaindole compounds TLR7, TLR9, TLR5 MMP12 2274/4885DRD1 1449/4885EGLN1 2914/4885
US-20090270431-A1 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections REV1, NSUN2, ORC3 MMP12 4759/4885DRD1 2093/4885EGLN1 3430/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MMP12 2274/4885DRD1 4862/4885EGLN1 1991/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MMP12 2274/4885DRD1 4862/4885EGLN1 1991/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A MMP12 3450/4885DRD1 4734/4885EGLN1 2627/4885
US-20200385382-A1 6-AZAINDOLE COMPOUNDS TLR7, TLR9, TLR5 MMP12 2274/4885DRD1 1449/4885EGLN1 2914/4885
US-20210253593-A1 SUBSTITUTED INDOLE COMPOUNDS TLR7, TLR1, HTR7 MMP12 1698/4885DRD1 997/4885EGLN1 630/4885
US-20200308172-A1 SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS TLR1, TLR7, TLR9 MMP12 2336/4885DRD1 905/4885EGLN1 1222/4885
US-11427580-B2 6-azaindole compounds TLR7, TLR9, TLR5 MMP12 2274/4885DRD1 1449/4885EGLN1 2914/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MMP12 2274/4885DRD1 4862/4885EGLN1 1991/4885
US-20210403468-A1 SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS TLR1, TLR7, IDO1 MMP12 3498/4885DRD1 859/4885EGLN1 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.